Abstract
Frequent endocrine alterations and abnormal growth hormone (GH) secretion have been reported in myotonic dystrophy (MD). To evaluate GH secretion status in MD, GH response to 100 μg of growth hormone releasing hormone (GHRH) with or without pyridostigmine pretreatment and its relation with insulin-induced hypoglycemia was investigated in MD patients and compared with normal controls. The mean peak plasma GH response to GHRH was 27.8 ± 19.2 μg/l normal subjects and 11.4 ± 8.7 μg/l in MD patients. In five of seven patients GH reached a mean peak of 12.6 ± 4.2 μg/l after insulin-induced hypoglycemia, compared with 5 ± 2.8 μg/l after GHRH. Conversely, in two patients GH reached a peak of 16.1 and 32 μg/l after GHRH, and only 2.5 and 5.3, respectively, after hypoglycemia. Pretreatment with pyridostigmine in nine patients tested potentiated GHRH-induced GH release with a peak of 17.6 ± 12.5 μg/l, compared with 10.05 ± 6.7 μg/l after GHRH alone; IGF-I levels were normal in all patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
